A Phase I/II Study of Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Trial Profile

A Phase I/II Study of Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
    • 19 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 30 Jun 2016 Study design changed from single group assignment to parallel assignment; Treatment arm changed from 1 to 3.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top